|
FDA Needs Ongoing, Public Approach to Risk-Benefit Assessments: IOM
The FDA needs to take an ongoing, lifecycle approach to assessing the risk-benefit profiles of new drugs and should seek more public input during the process, a new Institute of Medicine (IOM) report urges.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives